Medindia

X

Telik's TRAP Drug Discovery Technology Surpasses 3 Million Molecular Fingerprint Milestone

Tuesday, July 22, 2008 General News J E 4
Advertisement
PALO ALTO, Calif., July 22 Telik, Inc.(Nasdaq: TELK) announced today that its library of diverse profiled compoundsnow exceeds 3.3 million. The expanded library significantly enhances Telik'spatented drug discovery technology, Target Related Affinity Profiling(TRAP(R)). TRAP technology exploits the principle that drugs act by adheringto and interacting with key cellular proteins. Telik has developed a novelcomputational approach to determine a molecular fingerprint for each compoundin its library. TRAP technology uses these molecular fingerprints to rapidlysearch the library for promising lead molecules and to optimize thesestructures into new drug candidates. TRAP also allows the use of a wide rangeof biologically relevant assays. Several applications of the technology wererecently described at the 99th annual meeting of the American Association forCancer Research.

"This milestone is the latest achievement as we advance Telik's TRAPtechnology," said Robert Lum, Ph.D., Telik's Vice President of Technology andPreclinical Development. "This library of computational molecularfingerprints, combined with our proprietary data mining algorithms, will helpdrive the continued growth of Telik's pipeline of preclinical candidates."

TRAP technology has been the focus of several industry partnerships andcollaborations with leading academic cancer centers. Telik continues to seekadditional TRAP-based partnerships with corporations and academicinvestigators for the discovery and development of novel therapeutics.

About Telik

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused ondiscovering, developing and commercializing novel small molecule drugs totreat serious diseases. The company's most advanced investigational drugcandidates in clinical development are TELINTRA(R), a modified glutathioneanalog for the treatment of cytopenias due to myelodysplastic syndrome orchemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment ofadvanced ovarian cancer and non-small cell lung cancer. Telik's productcandidates were discovered using its proprietary drug discovery technology,TRAP, which enables the rapid and efficient discovery of small molecule drugcandidates. Additional information is available at http://www.telik.com.

This press release contains "forward-looking" statements, includingstatements regarding the potential capabilities of Telik's TRAP technology,the potential growth of Telik's preclinical drug candidates, the potentialdevelopment of existing and new partnerships and collaborations involvingTRAP, and the potential value of TRAP in the development of drugs andtherapies in connection with these partnerships. These forward-lookingstatements are based upon Telik's current expectations. There are importantfactors that could cause Telik's results to differ materially from thoseindicated by these forward-looking statements. Detailed information regardingfactors that may cause actual results to differ materially from the resultsexpressed or implied by statements in this press release may be found inTelik's periodic filings with the Securities and Exchange Commission,including the factors described in the section entitled "Risk Factors" in itsquarterly report on Form 10-Q for the quarter ended March 31, 2008. Telik doesnot undertake any obligation to update forward-looking statements contained inthis press release.

TELIK, the Telik logo, TELINTRA, TELCYTA, and TRAP are trademarks orregistered trademarks of Telik, Inc.

SOURCE Telik, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
MIMA Cancer Center Becomes First in World to Treat...
S
Hyperion Therapeutics Completes Enrollment in Phas...